Health-related quality of life and utility outcomes with selinexor in relapsed/refractory diffuse large B-cell lymphoma.
(2021) Future Oncology — Vol. 17, n° 11, p. 1295-1310 (2021)
Files
2021_Shah_Future_Oncol.pdf
Open Access - Adobe PDF
- 1.64 MB
Details
- Authors
- Abstract
- AIM: Evaluate health-related quality of life (HRQoL) and health utility impact of single-agent selinexor in heavily pretreated patients with relapsed/refractory diffuse large B-cell lymphoma. PATIENTS & METHODS: Functional Assessment of Cancer Therapy (FACT) - Lymphoma and EuroQoL five-dimensions five-levels data collected in the single-arm Phase IIb trial SADAL (NCT02227251) were analyzed with mixed-effects models. RESULTS: Treatment responders maintained higher FACT - Lymphoma (p ≤ 0.05), FACT - General (p < 0.05) and EuroQoL five-dimensions five-levels index scores (p < 0.001) beginning in cycle 3. The estimated difference in health state utilities for treatment response and progressive disease was both statistically significant and clinically meaningful (mean difference: 0.07; p = 0.001). CONCLUSION: In patients with relapsed/refractory diffuse large B-cell lymphoma, objective response to selinexor was associated with HRQoL maintenance, reduction in disease-related HRQoL decrements and higher health utilities.
- Affiliations
Citations
Shah, J., Shacham, S., Kauffman, M., Daniele, P., Tomaras, D., Tremblay, G., Casasnovas, R.-O., Maerevoet, M., Zijlstra, J., Follows, G., P Vermaat, J. S., Kalakonda, N., Goy, A. H., Choquet, S., Van Den Neste, E., Hill, B. T., Thieblemont, C., Cavallo, F., la Cruz, F. d., et al. (2021). Health-related quality of life and utility outcomes with selinexor in relapsed/refractory diffuse large B-cell lymphoma. Future Oncology, 17(11), 1295-1310. https://doi.org/10.2217/fon-2020-0946 (Original work published 2021)